1. Ultragenyx to participate in three upcoming investor conferences. 2. Fireside chats will feature key executives from Ultragenyx. 3. Company focuses on rare and ultra-rare genetic diseases. 4. RoI potential in novel therapies for unmet medical needs. 5. Management experienced in drug development and commercialization.
Participation in investor conferences often positively influences stock prices focusing on new products and strategies. Companies like Ultragenyx benefit from heightened investor interest in innovative therapeutics, potentially increasing RARE's market visibility.
The article highlights key events that can shape investor sentiment and potential stock performance. Growth in therapeutic areas represents a strategic advantage and can significantly influence RARE's investment outlook.
Investor conferences are near-term events likely to influence market sentiment quickly. The discussions can lead to immediate changes in investor perception and stock performance.
NOVATO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in three upcoming investor conferences.
Cantor Global Healthcare Conference 2025 (New York, NY)
Morgan Stanley 23rd Annual Global Healthcare Conference (New York, NY)
Bank of America Global Healthcare Conference (London, UK)
The live and archived webcast of the fireside chats will be accessible from the company's website at https://ir.ultragenyx.com/events-presentations.
About Ultragenyx
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contacts – Ultragenyx
Investors
Joshua Higa
ir@ultragenyx.com
